Purchase this article with an account.
Gwyneth A Van Rijn, Henri P Jongman, Jasper Wijnen, Gregorius P M Luyten, ; Long-term follow-up after Artisan phakic intraocular lens implantation in hyperopia.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2732.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the safety, efficacy, stability and complications of the Artisan iris-fixated phakic intraocular lens (pIOL) (Ophtec BV, Groningen, The Netherlands) for the correction of hyperopia.
Retrospective study of 62 eyes of 32 patients treated by one surgeon with a follow-up up to 16 years after Artisan pIOL implantation for the correction of hyperopia.
The mean pre-operative spherical equivalent was +6.48 (+/-1.98) diopters with an average CDVA (corrected distance visual acuity) of 0.89 (+/- 0.25) Snellen. Average follow-up time after implantation was 9.7 (+/-4.4) years. At the last follow-up the mean CDVA was 0.88 (+/- 0.33) Snellen with a safety index of 0.99 (+/-0.44). In 6.45% two or more lines of the CDVA were lost. A total of 11,3% of the pIOLs were explanted, with a mean time to explantation of 8.3 (+/-4.9) years. In 12.6% of the eyes posterior synechiae formation was observed after implantation. In 12.6% a (transient) elevated intraocular pressure was observed, yet none of the eyes developed glaucoma. Mean annual endothelial cell loss was 1.7 (+/- 3.6) percent.
Limited amount of long-term studies have been conducted to evaluate the safety of an iris-fixated pIOL for the correction of hyperopia, none are available with a follow up exceeding ten years. We assessed 62 eyes with a follow-up up to 16 years after implantation of an Artisan pIOL for the correction of hyperopia. A stable mean CDVA, with a good safety index was found after implantation. Rates of endothelial cell loss are higher than physiological cell loss of 0.6-0.9% per year. The most frequently observed complication was posterior synechiae formation. If strict pre-operative criteria are used for patient selection, the Artisan pIOL seems to be an effective, stable and safe method to correct hyperopia.
This PDF is available to Subscribers Only